产前预防应用沐舒坦降低早产儿RDS的临床观察

Clinical Observation on the Precaution Antepartum Application of Mucosolvin to Reduce the Morbidity of Premature Respiratory Distress Syndrome

目的观察产前预防应用沐舒坦对促胎肺成熟,降低早产儿呼吸窘迫综合征的发病率和死亡率的临床疗效观察。方法将85例早产孕妇随机分为2组,即治疗组和对照组。治疗组于产前预防应用沐舒坦治疗,对照组则应用糖皮质激素,对比产后早产儿呼吸窘迫综合征的发病率及程度、死亡率和感染发病率。结果早产儿呼吸窘迫综合征的发病率治疗组为14.0%,对照组为33.3%,差异有统计学意义(P<0.05)。发病程度、死亡率、感染发病率治疗组也明显低于对照组。结论产前预防应用沐舒坦可降低早产儿呼吸窘迫综合征的发病率和死亡率,提高早产儿存活率及生存质量。

[ Objective] To observe the clinical efficacy of the precaution antepartum application of Mucosolvin in promoting foetus lung maturity and reducing the morbidity of respiratory distress syndrome （ RDS）. [ Methods ] 85 gravidas of premature birth were randomly divided into two groups, namely, the treatment group and the control group; the treatment group was given Mucosolvin and the control group was given glucocorticoid ; the morbidity of RDS, mortality and infection rate of the two groups were compared. [ Results] The morbidity of RDS of the treatment group and the control group were 14.0% and 33.3% respectively, the difference was significant （ P 〈 0.05 ） ; the attack level, mortality and infection rate of the treatment group were significantly lower than that of the control. [ Conclusion] Precaution antepartum application of Mucosolvin can reduce the morbidity and mortality of RDS and improve the survival rate and life quality of the premature babies.